uniQure N.V. (NASDAQ:QURE - Get Free Report) crossed below its fifty day moving average during trading on Monday following insider selling activity. The stock has a fifty day moving average of $14.29 and traded as low as $13.65. uniQure shares last traded at $13.95, with a volume of 1,978,275 shares trading hands.
Specifically, insider Jeannette Potts sold 4,670 shares of uniQure stock in a transaction dated Monday, June 16th. The shares were sold at an average price of $15.14, for a total transaction of $70,703.80. Following the completion of the transaction, the insider now directly owns 115,073 shares of the company's stock, valued at $1,742,205.22. This trade represents a 3.90% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink.
Analyst Ratings Changes
Several equities research analysts have weighed in on QURE shares. Wells Fargo & Company lowered their price objective on shares of uniQure from $35.00 to $30.00 and set an "equal weight" rating for the company in a research report on Friday, February 28th. Cantor Fitzgerald upgraded shares of uniQure to a "strong-buy" rating in a research report on Monday, May 19th. Wall Street Zen cut shares of uniQure from a "hold" rating to a "sell" rating in a research report on Saturday, June 14th. Guggenheim restated a "buy" rating and issued a $28.00 price objective on shares of uniQure in a research report on Monday, May 12th. Finally, HC Wainwright restated a "buy" rating and issued a $70.00 price objective on shares of uniQure in a research report on Thursday, May 29th. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating, six have assigned a buy rating and two have issued a strong buy rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $37.82.
Read Our Latest Report on uniQure
uniQure Price Performance
The company has a debt-to-equity ratio of 1.53, a current ratio of 11.99 and a quick ratio of 11.99. The company's 50-day simple moving average is $14.29 and its 200-day simple moving average is $13.99. The stock has a market capitalization of $764.18 million, a P/E ratio of -3.18 and a beta of 0.08.
uniQure (NASDAQ:QURE - Get Free Report) last released its quarterly earnings data on Friday, May 9th. The biotechnology company reported ($0.82) EPS for the quarter, beating the consensus estimate of ($1.07) by $0.25. uniQure had a negative net margin of 1,077.05% and a negative return on equity of 483.87%. The firm had revenue of $1.57 million for the quarter, compared to the consensus estimate of $5.93 million. As a group, sell-side analysts expect that uniQure N.V. will post -3.75 EPS for the current fiscal year.
Hedge Funds Weigh In On uniQure
Several institutional investors and hedge funds have recently modified their holdings of the business. Woodline Partners LP grew its stake in shares of uniQure by 25.0% in the first quarter. Woodline Partners LP now owns 175,806 shares of the biotechnology company's stock valued at $1,864,000 after acquiring an additional 35,175 shares in the last quarter. 683 Capital Management LLC grew its stake in shares of uniQure by 1.6% in the first quarter. 683 Capital Management LLC now owns 1,550,000 shares of the biotechnology company's stock valued at $16,430,000 after acquiring an additional 25,000 shares in the last quarter. Vestal Point Capital LP lifted its position in uniQure by 58.4% during the first quarter. Vestal Point Capital LP now owns 4,792,572 shares of the biotechnology company's stock worth $50,801,000 after purchasing an additional 1,767,572 shares during the period. Birchview Capital LP lifted its position in uniQure by 343.5% during the first quarter. Birchview Capital LP now owns 88,697 shares of the biotechnology company's stock worth $940,000 after purchasing an additional 68,697 shares during the period. Finally, Nantahala Capital Management LLC lifted its position in uniQure by 3.8% during the first quarter. Nantahala Capital Management LLC now owns 2,755,962 shares of the biotechnology company's stock worth $29,213,000 after purchasing an additional 101,598 shares during the period. 78.83% of the stock is currently owned by institutional investors and hedge funds.
About uniQure
(
Get Free Report)
uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.
Further Reading
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider uniQure, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and uniQure wasn't on the list.
While uniQure currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are hedge funds and endowments buying in today's market? Enter your email address and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying now.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
